Evaluation of Dexamethasone treatment in high-risk covid19 patients in Qom

Ghoum University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2020年10月6日

适应症

试验速览

暂无简介。

•Age between 18 and 70 years
•Laboratory confirmation of Covid19 infection with reverse transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source
•The new organ dysfunction, which is related to Covid19, includes: Hypoxia requires supplemental oxygen to maintain oxygen saturation> 90%. hypotension (systolic blood pressure <90 mmHg) or need for vasopressor / inotropic drug.Renal impairment (especially creatinine) 50% of baseline, onset, received based on glomerular filtration film. Reduce the scale of Glasgow 2 or more, Thrombocytopenia (<150,000 platelets per millimeter). Symptoms of gastrointestinal upset requiring hospitalization (eg, severe nausea, vomiting, diarrhea, or abdominal pain

•Sensitivity or sensitivity to Lopinavir / Ritonavir or recombinant IFN-ß1b, including toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome.
•ALT above 5 times normal
•Use of drugs that are contraindicated with Lupinavir / RitonavirAnd do not replace or stop during the study period, such as CYP3A inhibitors.
•Pregnancy - Eligible female participants are tested at gestational age before enrolling in a pregnancy study.
•HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs.
•Uncontrolled diabetes (Prohibition of prednisolone).
•According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or inmates, are excluded from the study.

发起方

Ghoum University of Medical Sciences